\$20M Series A to commercialize the Endocrine Activity Index (EAI), a next-generation diagnostic to personalize breast cancer treatment

Take precision medicine for breast cancer to a new level with EAI


Solving for an unmet need: Current breast cancer diagnostic tests do not provide the information required for **optimal treatment decisions.**

EAI fills this need with:

delphi diagnostics[®]

- A portfolio of *innovative diagnostics developed at MD Anderson Cancer Center* to optimize treatment decisions and avoid non-beneficial treatment
- ✓ A gene expression profile that measures transcriptional activity related to Estrogen Receptor (ER) and Progesterone Receptor (PR) in breast cancer tumor tissue to yield an Index Score.

Market Overview



Clinical Evidence & EAI Utilities

Analytical & clinical validity proven

Prognostic for 5-year disease-free survival

Clinical Validity

clinically validated in multiple clinical trials with >4600 patients

- Speers, et al. 2023 (SWOG 8814)
- Metzger, et al. 2023 (CALGB 9741)
- Metzger, et al. ASCO 2024 (PALLAS)
- Penault-Llorca, et al. ASCO 2024 (PACS-01)

Analytical Validity

Predictive for benefit from taxane-based dose-intense chemotherapy

Clinical Validity demonstrated that doseintense treatment improved DFS and OS in node-positive stage II-III breast cancer patients N=613

 Metzger, et al. 2024 (CALGB 9741)

Analytical Validity

Combined Recurrence Score & Endocrine Activity Index Predictive for benefit from endocrine therapy

Clinical Validity

provides independent and additive information to the 21-gene Recurrence Score >750 patients

- Speers, et al. 2023 (SWOG 8814)
- 8814)Penault-Llorca, et al. ASCO
- 2024 (PACS-01) Strong Evidence

Strong Evidence
Penault-Llorca, et
al. ASCO 2024
(PACS-01)



Delphi Diagnostics Leadership Team

A vested team that knows how to execute





<u>Winz Casagrande</u> Chief Executive Officer

Andrew Levitch Chief Financial Officer



Dr. Federico Monzon Chief Medical Officer



J. Chuck Morrison Chief Commercial Officer

Intellectual Property



Patent strategy provides *exclusivity* and *protection* until 2045 *Exclusive worldwide license* from MD Anderson to commercialize EAI patent portfolio, including future innovations

Series A - \$20M

Use of Proceeds

Clinical Evidence Development —

- \$10.0M
- Multiple clinical studies across products to achieve clinical utility
- Development of Combined EAI & RS

Sales & Marketing –

\$5.5M

- Invest in sales personnel and programs to grow adoption
- Marketing support to increase awareness and education
- Coverage & Reimbursement

General & Administrative

\$4.5M

- IP enhancements
- Increased operational spending on systems and laboratory expansion
- Hires to support company growth

Contact

Chuck Morrison Chief Commercial Officer

jcmorrison@delphi-diagnostics.com